Jul 26, 2021 8:42am EDT Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients
Jun 18, 2021 6:45pm EDT Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock
May 25, 2021 8:00am EDT Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others
May 17, 2021 4:05pm EDT Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
Apr 21, 2021 8:00am EDT Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum
Apr 01, 2021 8:00am EDT Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
Mar 02, 2021 8:05am EST Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference
Feb 22, 2021 8:05am EST Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference
Feb 17, 2021 8:05am EST Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders
